# Single-dose,First-in-human of KLA478

> **NCT07240675** · PHASE1 · RECRUITING · sponsor: **Hunan Kelun Pharmaceutical Co., Ltd.** · enrollment: 40 (estimated)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** pramipexole hydrochloride sustained-release tablets
- **DRUG:** KLA478
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT07240675
- **Lead sponsor:** Hunan Kelun Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-26
- **Primary completion:** 2026-09-30
- **Final completion:** 2026-09-30
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07240675

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07240675, "Single-dose,First-in-human of KLA478". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT07240675. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*